Menu
  • Join
  • Login
  • Contact
 

Search abstracts


THE VALSARTAN SAGA: SCIENCE, MYTHS AND REALTIES

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: BALDACCHINO, Stephania (University of Malta, Pharmacy Department, Malta)
  • Co-author(s): Stephania Baldacchino: Pharmacy Department, University of Malta, Msida, Malta
    Anthony Serracino-Inglott: Malta Medicines Authority , Malta Medicines Authority, San Gwann, Malta;Pharmacy Department, University of Malta, Msida, Malta
    Annalise Attard: Malta Medicines Authority, Malta Medicines Authority, San Gwann, Malta
    Caroline Muscat: Malta Medicines Authority, Malta Medicines Authority, San Gwann, Malta
  • Abstract:

    Background

    Detection of N-nitrosodimethylamine (NDMA), a potential human carcinogen in the manufacture of the valsartan active pharmaceutical ingredient, led to the withdrawal of several contaminated valsartan medicinal products. 

    Methods

    Part I involved an in-depth analysis of the significance of the NDMA impurity in valsartan medicines through a

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses